InsiderSignal.AI

InsiderSignal.ai

IMNM - Immunome Inc.

Insider Purchase by Siegall Clay B (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Siegall Clay B, serving as Pres, CEO at Immunome Inc. (IMNM), purchased 25,450 shares at $19.67 per share, for a total transaction value of $500,602.00. Following this transaction, Siegall Clay B now holds 690,704 shares of IMNM.

This purchase represents a 4.00% increase in Siegall Clay B's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 31, 2026, 4 days after the trade was made.

Immunome Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Siegall Clay B

Siegall Clay B

Pres, CEO

Clay B. Siegall, Ph.D. is an American biopharmaceutical executive serving as President, Chief Executive Officer, and Chairman of Immunome Inc. (NASDAQ: IMNM) since October 2, 2023, following the merger with Morphimmune, where he was also President and CEO.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[3]](https://www.shattucklabs.com/clay-siegall/) Age 64, Dr. Siegall is a recognized leader in oncology drug development, particularly antibody-drug conjugates (ADCs).[[3]](https://www.shattucklabs.com/clay-siegall/)[[5]](https://lifesciencewa.org/speakers/clay-siegall-phd/) Dr. Siegall co-founded Seagen Inc. (formerly Seattle Genetics) in 1997, serving as CEO (2002–2022), President (2000–2022), and Chairman (2004–2022), transforming it into a global leader in ADC therapeutics with four FDA-approved cancer therapies, over $2 billion in annual revenue, and its $43 billion acquisition by Pfizer in 2023.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[3]](https://www.shattucklabs.com/clay-siegall/)[[5]](https://lifesciencewa.org/speakers/clay-siegall-phd/) Earlier, he held roles at Bristol-Myers Squibb Pharmaceutical Research Institute (1991–1997) and the National Cancer Institute (1988–1991).[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[4]](https://www.youtube.com/watch?v=ZKJdQxD80A8) He holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.[[1]](https://www.zoominfo.com/p/Clay-Siegall/5740410596)[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)[[4]](https://www.youtube.com/watch?v=ZKJdQxD80A8) Currently, he chairs the boards of Tourmaline Bio and serves as a director at Shattuck Labs, among other roles.[[2]](https://fintool.com/app/research/companies/IMNM/people/clay-siegall)

View full insider profile →

Trade Price

$19.67

Quantity

25,450

Total Value

$500,602.00

Shares Owned

690,704

Trade Date

Friday, March 27, 2026

9 days ago

SEC Filing Date

Tuesday, March 31, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Immunome Inc.

Company Overview

No company information available
View news mentioning IMNM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5244251

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime